Related Experiment Video
Updated: Jan 20, 2026
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Preventive Antiepileptic Treatment in Tuberous Sclerosis Complex: A Long-Term, Prospective Trial
Sergiusz Jozwiak1, Monika Słowińska2, Julita Borkowska3
1Department of Child Neurology, Warsaw Medical University, Warsaw, Poland; Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland.
Insights
Preventive antiepileptic treatment in infants with tuberous sclerosis complex (TSC) significantly improves epilepsy control and cognitive outcomes. Early intervention with vigabatrin can prevent clinical seizures and reduce intellectual disability risk in children with TSC.
Area of Science:
- Neurology
- Pediatrics
- Epileptology
Background:
- Drug-resistant epilepsy in tuberous sclerosis complex (TSC) is a primary risk factor for intellectual disability.
- Electroencephalographic changes often precede clinical epileptic seizures, offering a window for preventive interventions.
- Evaluating long-term neurodevelopmental and epilepsy outcomes in TSC patients receiving early antiepileptic treatment.
Purpose of the Study:
- To assess the efficacy of preventive antiepileptic treatment initiated in infancy for children with tuberous sclerosis complex.
- To compare epilepsy and neuropsychological outcomes at school age between infants with TSC receiving preventive versus standard vigabatrin treatment.
- To determine if early intervention impacts the development of intellectual disability in TSC.
Main Methods:
- A prospective, nonrandomized clinical trial involving 14 infants with TSC who received preventive vigabatrin based on electroencephalographic findings.
- An age-matched control group of 31 TSC infants received vigabatrin only after the onset of clinical seizures.
- Clinical assessment of epilepsy and cognitive outcomes analyzed through school age.
Main Results:
- The preventive group (n=14) showed a median intelligence quotient (IQ) of 94 compared to 46 in the standard group (n=25) (P < 0.03).
- 50% of patients in the preventive group remained seizure-free, versus 5% in the standard treatment group (P = 0.001).
- Follow-up extended to a median of 8.8 years for the preventive group and 8.0 years for the standard group.
Conclusions:
- Preventive antiepileptic treatment in infants with TSC significantly improves long-term epilepsy control.
- Early intervention with vigabatrin in TSC infants leads to better cognitive outcomes at school age.
- Proactive treatment based on electroencephalographic monitoring is crucial for mitigating epilepsy and intellectual disability in TSC.
Backgroud:
Drug-resistant epilepsy is the main risk factor for future intellectual disability in patients with tuberous sclerosis complex. Clinical epileptic seizures are often preceded by electroencephalographic changes, which provide an opportunity for preventive treatment. We evaluated the neuropsychologic and epilepsy outcomes at school age in children with tuberous sclerosis complex who received preventive antiepileptic treatment in infancy.
Methods:
We performed a prospective, nonrandomized clinical trial with 14 infants diagnosed with tuberous sclerosis complex in whom serial electroencephalographic recordings were performed and preventive treatment with vigabatrin initiated when active epileptic discharges were detected. An age-matched control group consisted of 31 infants with tuberous sclerosis complex in whom treatment with vigabatrin was given only after onset of clinical seizures. Results of clinical assessment of epilepsy and cognitive outcomes were analyzed.
Results:
All patients in the preventive group (n = 14) and 25 of 31 patients in the standard treatment group were followed through minimum age five years, median 8.8 and 8.0 years in the preventive and standard groups, respectively. The median intelligence quotient was 94 for the preventive group when compared with 46 for the standard group (P < 0.03). Seven of 14 patients (50%) in the preventive group never had a clinical seizure when compared with one of 25 patients (5%) in the standard treatment group (P = 0.001).
Conclusions:
This study provides evidence that preventive antiepileptic treatment in infants with tuberous sclerosis complex improves long-term epilepsy control and cognitive outcome at school age.
Related Concept Videos
06:41Prospect Theory
11:35The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
09:41Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
08:54Measuring Endoreduplication by Flow Cytometry of Isolated Tuber Protoplasts
06:57Rapid High Throughput Amylose Determination in Freeze Dried Potato Tuber Samples
08:11Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis